{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:50:08Z","timestamp":1765889408029,"version":"3.32.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.yebeh.2024.110073","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T21:24:41Z","timestamp":1730409881000},"page":"110073","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Adverse events associated with Stiripentol in children aged 0\u201317\u00a0years: An analysis of a real-world pharmacovigilance database"],"prefix":"10.1016","volume":"161","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4930-7685","authenticated-orcid":false,"given":"Tianyu","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuezhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.yebeh.2024.110073_b0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1528-1167.2011.02994.x","article-title":"The core Dravet syndrome phenotype","volume":"52","author":"Dravet","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.110073_b0010","article-title":"The psychosocial impact of caring for children with Dravet Syndrome","volume":"24","author":"Salom","year":"2023","journal-title":"Epilepsy Behav Rep"},{"issue":"15","key":"10.1016\/j.yebeh.2024.110073_b0015","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s40265-023-01936-y","article-title":"Pharmacotherapy for Dravet syndrome: a systematic review and network meta-analysis of randomized controlled trials","volume":"83","author":"Lattanzi","year":"2023","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.yebeh.2024.110073_b0020","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40263-022-00898-1","article-title":"Schubert-BS.A practical guide to the treatment of Dravet syndrome with anti-seizure medication","volume":"36","author":"Strzelczyk","year":"2022","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.yebeh.2024.110073_b0025","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/14737175.2023.2195550","article-title":"Stiripentol for the treatment of seizures associated with Dravet syndrome in patients 6 months and older and taking clobazam","volume":"23","author":"Vasquez","year":"2023","journal-title":"Expert Rev Neurother"},{"issue":"4","key":"10.1016\/j.yebeh.2024.110073_b0030","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s12325-024-02813-0","article-title":"An Update on Stiripentol Mechanisms of Action: A Narrative Review","volume":"41","author":"Bacq","year":"2024","journal-title":"Adv Ther"},{"issue":"12","key":"10.1016\/j.yebeh.2024.110073_b0035","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/dmcn.15638","article-title":"Initiating Stiripentol before 2 years of age in patients with Dravet syndrome is safe and beneficial against status epilepticus","volume":"65","author":"Chiron","year":"2023","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.yebeh.2024.110073_b0040","unstructured":"Diacomit: prescribing information.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/206709s000,207223s000lbl.pdf. Accessed Mar 2024."},{"issue":"3","key":"10.1016\/j.yebeh.2024.110073_b0045","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s40801-022-00305-7","article-title":"Efficacy and safety of long-term treatment with Stiripentol in children and adults with drug-resistant epilepsies: a retrospective cohort study of 196 patients","volume":"9","author":"Balestrini","year":"2022","journal-title":"Drugs Real World Outcomes"},{"key":"10.1016\/j.yebeh.2024.110073_b0050","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s40264-016-0413-1","article-title":"Signal of gastrointestinal congenital malformations with antipsychotics after minimising competition bias: a disproportionality analysis using data from Vigibase","volume":"39","author":"Montastruc","year":"2016","journal-title":"Drug Saf"},{"key":"10.1016\/j.yebeh.2024.110073_b0055","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1248\/yakushi.16-00219","article-title":"Evaluation of the expression profile of extrapyramidal symptoms due to antipsychotics by data mining of Japanese Adverse Drug Event Report (JADER) Database","volume":"137","author":"Kose","year":"2017","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.yebeh.2024.110073_b0060","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1177\/009127009803801103","article-title":"Gender differences in adverse drug reactions","volume":"38","author":"Tran","year":"1988","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2024.110073_b0065","doi-asserted-by":"crossref","first-page":"1283247","DOI":"10.3389\/fphar.2023.1283247","article-title":"Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database","volume":"14","author":"Liu","year":"2023","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.yebeh.2024.110073_b0070","doi-asserted-by":"crossref","first-page":"24955","DOI":"10.1038\/srep24955","article-title":"Systematic Analysis of Adverse Event Reports for Sex Differences in Adverse Drug Events","volume":"22","author":"Yu","year":"2016","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.yebeh.2024.110073_b0075","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/epi4.12847","article-title":"Efficacy and tolerability of add-on Stiripentol in real-world clinical practice: An observational study in Dravet syndrome and non-Dravet developmental and epileptic encephalopathies","volume":"9","author":"Gil-Nagel","year":"2024","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2024.110073_b0080","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.eplepsyres.2015.03.012","article-title":"STP-1 Study Group. Long-term safety and efficacy of Stiripentol for the treatment of Dravet syndrome: A multicenter, open-label study in Japan","volume":"113","author":"Inoue","year":"2015","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2024.110073_b0085","unstructured":"Chen WJ. Progress of add-on Stiripentol therapy in children with Dravet syndrome. Int J Pediatr,2019;46(7),469-472. dio:10.3760\/cma.j.issn.1673-4408.2019.07.003."},{"key":"10.1016\/j.yebeh.2024.110073_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2019.106459","article-title":"Drug-drug interactions and pharmacodynamics of concomitant clobazam and cannabidiol or Stiripentol in refractory seizures","volume":"99","author":"Klein","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2024.110073_b0095","doi-asserted-by":"crossref","DOI":"10.1111\/dmcn.13704","article-title":"Stiripentol efficacy and safety in Dravet syndrome: a 12-year observational study[J]","author":"Myers","year":"2018","journal-title":"Dev Med Child Neurol"},{"issue":"3","key":"10.1016\/j.yebeh.2024.110073_b0100","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40263-022-00898-1","article-title":"A practical guide to the treatment of Dravet syndrome with anti-seizure medication","volume":"36","author":"Strzelczyk","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2024.110073_b0105","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.eplepsyres.2016.12.014","article-title":"Add-on Stiripentol elevates serum valproate levels in patients with or without concomitant topiramate therapy","volume":"130","author":"Jogamoto","year":"2017","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2024.110073_b0110","doi-asserted-by":"crossref","unstructured":"Thanh TN., Chiron C, Dellatolas G., Rey E., Pons G., Vincent J., et al. Efficacit\u00e9 et tol\u00e9rance \u00e0 long terme du Stiripentol dans le traitement de l'\u00e9pilepsie myoclonique s\u00e9v\u00e8re du nourrisson (syndrome de Dravet) [Long-term efficacy and tolerance of stiripentaol in severe myoclonic epilepsy of infancy (Dravet's syndrome)]. Arch Pediatr. 2002 Nov;9(11):1120-7. French. doi: 10.1016\/s0929-693x(02)00090-8.","DOI":"10.1016\/S0929-693X(02)00090-8"},{"key":"10.1016\/j.yebeh.2024.110073_b0115","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.brainresrev.2007.06.026","article-title":"Hyperammonemia-induced toxicity for the developing central nervous system","volume":"56","author":"Laur\u00e8ne","year":"2007","journal-title":"Brain Res Rev"},{"issue":"4","key":"10.1016\/j.yebeh.2024.110073_b0120","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s10545-008-0834-9","article-title":"Profiling of astrocyte properties in the hyperammonaemic brain: shedding new light on the pathophysiology of the brain damage in hyperammonaemia","volume":"31","author":"Lichter-Konecki","year":"2008","journal-title":"J Inherit Metab Dis"},{"issue":"11","key":"10.1016\/j.yebeh.2024.110073_b0125","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1111\/epi.16684","article-title":"Starting Stiripentol in adults with Dravet syndrome?","volume":"61","author":"Zulfiqar","year":"2020","journal-title":"Watch for ammonia and carnitine Epilepsia"},{"issue":"5","key":"10.1016\/j.yebeh.2024.110073_b0130","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bcpt.13049","article-title":"Risk factors for valproic acid-induced hyperammonaemia in chinese paediatric patients with epilepsy","volume":"123","author":"Zhu","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"6","key":"10.1016\/j.yebeh.2024.110073_b0135","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/epi.12125","article-title":"Risk factors for hyperammonemia in pediatric patients with epilepsy","volume":"54","author":"Yamamoto","year":"2013","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.yebeh.2024.110073_b0140","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1080\/17512433.2017.1353418","article-title":"The effect of antiepileptic drugs on the kidney function and structure","volume":"10","author":"Hamed","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.yebeh.2024.110073_b0145","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s40263-017-0432-1","article-title":"Stiripentol in the management of epilepsy","volume":"31","author":"Nickels","year":"2017","journal-title":"CNS Drugs"},{"issue":"13","key":"10.1016\/j.yebeh.2024.110073_b0150","doi-asserted-by":"crossref","first-page":"7162","DOI":"10.3390\/ijms22137162","article-title":"Antiepileptic Stiripentol may influence bones","volume":"22","author":"Matuszewska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.yebeh.2024.110073_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107832","article-title":"Drug-induced liver injury associated with antiseizure medications from the FDA Adverse Event Reporting System (FAERS)","volume":"117","author":"Kamitaki","year":"2021","journal-title":"Epilepsy Behav"},{"issue":"2","key":"10.1016\/j.yebeh.2024.110073_b0160","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1055\/s-2008-1073117","article-title":"Acute liver failure due to drugs","volume":"28","author":"Fontana","year":"2008","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.yebeh.2024.110073_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2020.106535","article-title":"Long-term safety and effectiveness of Stiripentol in patients with Dravet syndrome: Interim report of a post-marketing surveillance study in Japan","volume":"170","author":"Yamada","year":"2021","journal-title":"Epilepsy Res"},{"issue":"4","key":"10.1016\/j.yebeh.2024.110073_b0170","first-page":"277","article-title":"Clinical and neuroimaging features of acute encephalopathy after status epilepticus in Dravet syndrome","volume":"55","author":"Tian","year":"2017","journal-title":"Chin J Pediatr"},{"issue":"6","key":"10.1016\/j.yebeh.2024.110073_b0175","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/j.1528-1167.2007.01020.x","article-title":"Brain MRI findings in severe myoclonic epilepsy in infancy and genotype-phenotype correlations","volume":"48","author":"Striano","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.110073_b0180","unstructured":"US Department of Health and Human Services. Statistical review and evaluation: antiepileptic drugs and suicidality. Accessed June 24, 2021.https:\/\/www.fda.gov\/files\/drugs\/published\/Statistical-Review-and-Evaluation--Antiepileptic-Drugs-and-Suicidality.pdf."},{"issue":"9","key":"10.1016\/j.yebeh.2024.110073_b0185","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1001\/jamaneurol.2021.2480","article-title":"Suicidality risk of newer antiseizure medications: a meta-analysis","volume":"78","author":"Klein","year":"2021","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1016\/j.yebeh.2024.110073_b0190","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1177\/1945892420920505","article-title":"Exploring balloon sinuplasty adverse events with the innovative OpenFDA Database","volume":"34","author":"Wright","year":"2020","journal-title":"Am J Rhinol Allergy"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505024004554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505024004554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T12:39:52Z","timestamp":1734611992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505024004554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":38,"alternative-id":["S1525505024004554"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2024.110073","relation":{},"ISSN":["1525-5050"],"issn-type":[{"type":"print","value":"1525-5050"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse events associated with Stiripentol in children aged 0\u201317\u00a0years: An analysis of a real-world pharmacovigilance database","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2024.110073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110073"}}